Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC
Status:
Unknown status
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
This is a clinical study of Apatinib Mesylate Tablets combined with docetaxel monotherapy as
second-line therapy of advanced EGFR wild-type, non-squamous, non-small-cell lung cancer.